Evogene Ltd. announced on July 8, 2025, the successful completion and closing of the transaction involving the divestiture of the majority of the activities and assets of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd. This finalizes the agreement initially announced on April 21, 2025.
As part of the transaction, ICL has acquired Lavie Bio's proprietary Biology Driven Design (BDD) technology platform, its microbial bank, pipeline of advanced development programs, and current commercial product offerings. Lavie Bio's core personnel will also transfer to ICL, ensuring continuity and expertise.
Additionally, Evogene transferred its MicroBoost AI for Agriculture computational engine to ICL, which is designed to optimize microbial discovery and development through artificial intelligence. This acquisition strengthens ICL's drive to lead the global ag-biologicals market by integrating innovative capabilities with its R&D expertise and global sales network.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.